GDRX Stock Price, GoodRx Holdings Inc Quote, Chart

Market Summary

USD7.48-0.58

Delayed

-7.20%

GDRX Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

GDRX Stock Price

View Fullscreen

GDRX RSI Chart

GDRX Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-442.93

Price/Sales (Trailing)

3.82

EV/EBITDA

28.06

Price/Free Cashflow

19.81

GDRX Price/Sales (Trailing)

GDRX Profitability

EBT Margin

-7.70%

Return on Equity

-1.04%

Return on Assets

-0.45%

Free Cashflow Yield

5.05%

GDRX Fundamentals

GDRX Revenue

Revenue (TTM)

764.2M

Rev. Growth (Yr)

7.55%

Rev. Growth (Qtr)

0.63%

GDRX Earnings

Earnings (TTM)

-6.6M

Earnings Growth (Yr)

69.33%

Earnings Growth (Qtr)

96.1%

Breaking Down GDRX Revenue

Last 7 days

13.3%

Last 30 days

15.1%

Last 90 days

16.0%

Trailing 12 Months

45.5%

How does GDRX drawdown profile look like?

GDRX Financial Health

Current Ratio

6.29

Debt/Equity

1.02

Debt/Cashflow

0.23

GDRX Investor Care

Buy Backs (1Y)

5.43%

Diluted EPS (TTM)

-0.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	764.2M	0	0	0
2023	747.2M	745.1M	737.7M	750.3M
2022	788.3M	803.5M	795.7M	766.6M
2021	577.7M	631.1M	685.7M	745.4M
2020	428.8M	469.5M	510.1M	550.7M
2019	0	0	318.9M	388.2M
2018	0	0	0	249.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of GoodRx Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	nabiey romin	acquired	-	-	12,662	chief accounting officer
May 08, 2024	wagner scott	sold (taxes)	-189,666	7.53	-25,188	see remarks
May 08, 2024	nabiey romin	sold (taxes)	-34,020	7.53	-4,518	chief accounting officer
May 08, 2024	wagner scott	acquired	-	-	70,592	see remarks
Apr 15, 2024	nabiey romin	acquired	-	-	2,606	chief accounting officer
Apr 15, 2024	nabiey romin	sold (taxes)	-6,351	6.83	-930	chief accounting officer
Mar 08, 2024	voermann karsten	acquired	-	-	54,064	chief financial officer
Mar 08, 2024	nabiey romin	sold (taxes)	-28,237	7.54	-3,745	chief accounting officer
Mar 08, 2024	voermann karsten	sold (taxes)	-129,990	7.54	-17,240	chief financial officer
Mar 08, 2024	nabiey romin	acquired	-	-	10,201	chief accounting officer

Which funds bought or sold GDRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	27.09	299,425	1,162,760	-%
May 16, 2024	INNEALTA CAPITAL, LLC	unchanged	-	5,422	96,241	0.04%
May 16, 2024	Beacon Capital Management, LLC	new	-	28,400	28,400	0.01%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	5.1	51,439	503,475	-%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	new	-	239,980	239,980	0.04%
May 15, 2024	TWO SIGMA ADVISERS, LP	added	8.1	822,290	6,473,070	0.01%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	sold off	-100	-1,745,660	-	-%
May 15, 2024	Graham Capital Management, L.P.	reduced	-69.61	-604,194	287,067	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	reduced	-79.25	-316,710	89,290	-%
May 15, 2024	Man Group plc	new	-	329,674	329,674	-%

Are Funds Buying or Selling GDRX?

Are funds buying GDRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GDRX

No. of Funds

Unveiling GoodRx Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 02, 2024	millennium management llc	5.1%	4,833,570	SC 13G
Mar 08, 2024	francisco partners iv, l.p.	28.6%	46,680,496	SC 13D/A
Mar 08, 2024	spectrum equity vii, l.p.	24.2%	29,825,306	SC 13D/A
Feb 14, 2024	ameriprise financial inc	7.58%	7,001,503	SC 13G
Feb 13, 2024	vanguard group inc	9.07%	8,380,990	SC 13G/A
Feb 12, 2024	rubric capital management lp	6.36%	5,872,806	SC 13G
Jan 25, 2024	millennium management llc	0.7%	602,934	SC 13G/A
Nov 21, 2023	spectrum equity vii, l.p.	30.9%	36,048,589	SC 13D/A
Oct 27, 2023	hirsch douglas joseph	5.5%	5,120,852	SC 13D/A
Oct 27, 2023	bezdek trevor	5.5%	5,120,852	SC 13D/A

Recent SEC filings of GoodRx Holdings Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 08, 2024	4	Insider Trading
May 08, 2024	4	Insider Trading
May 02, 2024	EFFECT	EFFECT
May 02, 2024	SC 13G	Major Ownership Report
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	ARS	ARS
Apr 16, 2024	4	Insider Trading

Peers (Alternatives to GoodRx Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

GoodRx Holdings Inc News

Latest updates

GoodRx Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Revenue	0.6%	198	197	180	190	184	184	187	192	203	213	195	177	160	154	140	123	133	118	102	-
Costs and Expenses	-11.4%	190	215	218	171	173	182	203	196	184	202	188	177	165	453	202	82.00	90.00	-	64.00	-
S&GA Expenses	-4.0%	90.00	94.00	92.00	77.00	79.00	84.00	86.00	94.00	93.00	106	96.00	88.00	80.00	75.00	65.00	52.00	63.00	-	45.00	-
R&D Expenses	-3.2%	31.00	32.00	40.00	31.00	33.00	37.00	36.00	35.00	35.00	35.00	35.00	30.00	26.00	24.00	16.00	12.00	10.00	-	8.00	-
EBITDA Margin	-2.5%	0.14*	0.15*	0.13*	0.13*	0.09*	0.09*	0.08*	0.10*	0.10*	0.06*	-0.39*	-0.54*	-0.53*	-0.47*	0.29*	0.31*	0.34*	0.38*	0.26*	0.34*
Interest Expenses	-1.2%	15.00	15.00	15.00	14.00	13.00	12.00	9.00	7.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	7.00	9.00	-	13.00	-
Income Taxes	5.5%	1.00	1.00	-8.11	-46.72	7.00	-2.77	19.00	-8.74	2.00	46.00	19.00	-37.30	-12.55	-7.36	-17.89	8.00	8.00	-	6.00	-
Earnings Before Taxes	101.2%	0.00	-24.63	-46.60	12.00	4.00	-4.74	-22.27	-10.16	14.00	6.00	1.00	-6.24	-10.89	-305	-67.93	35.00	35.00	-	25.00	-
EBT Margin	-4.0%	-0.08*	-0.07*	-0.05*	-0.02*	-0.04*	-0.03*	-0.02*	0.01*	0.02*	-0.01*	-0.47*	-0.62*	-0.60*	-0.55*	0.16*	0.18*	0.19*	0.21*	0.16*	0.21*
Net Income	96.1%	-1.01	-25.87	-38.49	59.00	-3.29	-1.97	-41.73	-1.41	12.00	-39.91	-18.07	31.00	2.00	-298	-50.03	27.00	27.00	15.00	20.00	-
Net Income Margin	27.1%	-0.01*	-0.01*	0.02*	0.02*	-0.06*	-0.04*	-0.09*	-0.06*	-0.02*	-0.03*	-0.41*	-0.50*	-0.55*	-0.53*	0.04*	0.19*	0.19*	0.17*	0.14*	0.18*
Free Cashflow	172.8%	42.00	15.00	60.00	30.00	32.00	32.00	33.00	50.00	28.00	49.00	48.00	35.00	43.00	10.00	19.00	37.00	45.00	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-8.5%	1,454	1,589	1,708	1,692	1,612	1,605	1,567	1,592	1,538	1,608	1,614	1,587	1,511	1,470	1,547	387
Current Assets	-16.0%	733	873	969	919	907	920	878	894	995	1,089	1,052	1,076	1,123	1,086	1,181	87.00
Cash Equivalents	-20.7%	533	672	795	762	761	757	729	731	845	941	912	895	990	969	1,075	26.00
Net PPE	-3.7%	15.00	16.00	17.00	18.00	19.00	20.00	22.00	23.00	23.00	22.00	22.00	22.00	23.00	23.00	17.00	2.00
Goodwill	0%	411	411	412	412	412	412	415	415	81.00	330	330	320	261	261	261	236
Liabilities	-0.5%	823	827	827	797	784	790	779	774	752	776	768	763	762	759	790	737
Current Liabilities	-4.9%	117	123	118	83.00	69.00	76.00	85.00	80.00	59.00	81.00	73.00	65.00	63.00	60.00	60.00	33.00
Long Term Debt	-0.2%	647	648	649	650	651	652	653	654	655	656	657	658	659	660	689	664
LT Debt, Current	-20.0%	7.00	9.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00
LT Debt, Non Current	-100.0%	-	648	649	650	651	652	653	654	655	656	657	658	659	660	689	664
Shareholder's Equity	-17.2%	631	762	881	895	827	815	788	818	787	832	846	824	749	711	756	-
Retained Earnings	-0.1%	-1,458	-1,457	-1,431	-1,393	-1,451	-1,448	-1,446	-1,404	-1,403	-1,415	-1,375	-1,357	-1,388	-1,390	-1,092	-1,096
Additional Paid-In Capital	-5.9%	2,089	2,219	2,313	2,288	2,279	2,263	2,235	2,223	2,190	2,247	2,222	2,182	2,138	2,102	1,849	9.00
Shares Outstanding	-4.9%	390	410	413	412	412	413	413	413	415	410	409	408	406	275	241	227
Float	-	-	-	-	424	-	-	-	472	-	-	-	2,300	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	168.4%	42,586	15,868	60,270	29,866	32,288	31,879	33,732	51,049	30,120	49,810	48,558	34,926	45,485	14,850	32,666	38,233	45,592	-	-	-
Share Based Compensation	-12.8%	25,096	28,778	32,646	17,897	25,499	56,350	3,200	3,600	30,149	16,800	3,000	3,900	46,526	232,100	6,800	400	2,210	-	700	-
Cashflow From Investing	-60.2%	-20,615	-12,872	-13,647	-14,959	-14,288	1,286	-13,775	-163,608	-34,401	-9,259	-27,058	-132,721	-9,695	-9,810	-73,488	-4,912	-3,407	-	-	-
Cashflow From Financing	-28.2%	-160,972	-125,605	-13,706	-13,994	-14,090	-4,786	-21,711	-2,328	-91,401	-11,465	-4,180	-865	-14,018	-111,373	992,121	-2,533	27,602	-	-	-
Buy Backs	98.9%	154,814	77,825	7,712	8,920	9,517	-	17,956	-	83,765	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GDRX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 197,880	$ 183,986
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below	12,468	16,695
Product development and technology	31,017	32,908
Sales and marketing	89,964	78,522
General and administrative	41,108	29,619
Depreciation and amortization	15,942	14,939
Total costs and operating expenses	190,499	172,683
Operating income	7,381	11,303
Other expense, net:
Other expense	0	(1,808)
Interest income	7,555	7,234
Interest expense	(14,643)	(13,133)
Total other expense, net	(7,088)	(7,707)
Income before income taxes	293	3,596
Income tax expense	(1,302)	(6,886)
Net loss	$ (1,009)	$ (3,290)
Loss per share:
Basic (in usd per share)	$ (0.00)	$ (0.01)
Diluted (in usd per share)	$ (0.00)	$ (0.01)
Weighted average shares used in computing loss per share:
Basic (in shares)	390,048	412,429
Diluted (in shares)	390,048	412,429
Cost of revenue
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 76	$ 161
Product development and technology
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	5,848	8,589
Sales and marketing
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	8,127	4,412
General and administrative
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 11,045	$ 12,337

GDRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 533,295	$ 672,296
Accounts receivable, net	144,769	143,608
Prepaid expenses and other current assets	54,735	56,886
Total current assets	732,799	872,790
Property and equipment, net	15,341	15,932
Goodwill	410,769	410,769
Intangible assets, net	58,122	60,898
Capitalized software, net	103,980	95,439
Operating lease right-of-use assets, net	30,928	29,929
Deferred tax assets, net	65,268	65,268
Other assets	36,756	37,775
Total assets	1,453,963	1,588,800
Current liabilities
Accounts payable	33,518	36,266
Accrued expenses and other current liabilities	70,843	71,329
Current portion of debt	7,029	8,787
Operating lease liabilities, current	5,131	6,177
Total current liabilities	116,521	122,559
Debt, net	646,678	647,703
Operating lease liabilities, net of current portion	51,339	48,403
Other liabilities	8,356	8,177
Total liabilities	822,894	826,842
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.0001 par value; 50,000 shares authorized and zero shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 94,074 and 92,355 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively; and Class B: 1,000,000 shares authorized, 280,869 and $301,732 shares issued and outstanding at March 31, 2024 and December 31, 2023	38	40
Additional paid-in capital	2,089,443	2,219,321
Accumulated deficit	(1,458,412)	(1,457,403)
Total stockholders' equity	631,069	761,958
Total liabilities and stockholders' equity	$ 1,453,963	$ 1,588,800

About GoodRx Holdings Inc

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is headquartered in Santa Monica, California.

WEBSITE	goodrx.com
INDUSTRY	Healthcare Plans
EMPLOYEES	952

GoodRx Holdings Inc Frequently Asked Questions

What is the ticker symbol for GoodRx Holdings Inc? What does GDRX stand for in stocks?

GDRX is the stock ticker symbol of GoodRx Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GoodRx Holdings Inc (GDRX)?

As of Fri May 17 2024, market cap of GoodRx Holdings Inc is 2.92 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GDRX stock?

You can check GDRX's fair value in chart for subscribers.

What is the fair value of GDRX stock?

You can check GDRX's fair value in chart for subscribers. The fair value of GoodRx Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GoodRx Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GDRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GoodRx Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether GDRX is over valued or under valued. Whether GoodRx Holdings Inc is cheap or expensive depends on the assumptions which impact GoodRx Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GDRX.

What is GoodRx Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, GDRX's PE ratio (Price to Earnings) is -442.93 and Price to Sales (PS) ratio is 3.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GDRX PE ratio will change depending on the future growth rate expectations of investors.